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Abstract 
 
GENETIC MANIPULATION OF THE RELAPSING FEVER SPIROCHETE BORRELIA 
HERMSII PERMITS NOVEL INVESTIGATION INTO THE ROLE OF FACTOR H BINDING 
IN BORRELIAL VIRULENCE 
 
By Lindy M. Fine, B.A. 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science 
at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2011 
Director: Richard T. Marconi, Ph.D. 
Professor, Department of Microbiology and Immunology 
 
Borrelia hermsii, an etiologic agent of tick-borne relapsing fever, binds negative 
complement regulator factor H (FH) via its FhbA protein. Direct demonstration of the role of 
FhbA in the disease process has been hindered by the lack of genetic manipulation systems for 
the relapsing fever Borrelia. Here, we demonstrate successful generation of a B. hermsii strain 
YOR fhbA deletion mutant (Bh YORΔfhbA) that constitutively produces green fluorescent 
protein (GFP). Genetic manipulation did not affect growth rate or plasmid composition. Bh 
YORΔfhbA lost factor H-binding and C3b-inactivation capabilities, but retained resistance to 
killing in human serum and infectivity in mice. Stable production of GFP was demonstrated in 
vitro and in vivo. Collectively, these results suggest that B. hermsii employs an unidentified 
mechanism of complement evasion that is FH-independent and sufficient for persistence within 
the host. Additionally, this study represents a significant methodological advancement in the
 
 
molecular characterization of relapsing fever spirochetes. 
 
Introduction 
 
Borrelia and human health 
 Pathogenic Borrelia species include the causative agents of Lyme disease and relapsing 
fever (14, 157), earning the genus an important place in the history of public health. Lyme 
disease (LD) is a significant infectious disease of modern times, and has undergone marked 
range expansion since it was first recognized in the United States several decades ago (71, 158). 
Currently, Lyme disease, caused by B. burgdorferi in North America and B. burgdorferi, B. 
garinii, and B. afzelii in Europe (7, 97), is the most common tick-borne disease in the Northern 
Hemisphere (32, 156, 174). 
Relapsing fever (RF) is an ancient disease that was documented during the time of 
Hippocrates. However, it was not until 1873 that a spirochetal etiologic agent of the louse-borne 
form of relapsing fever was identified. In the centuries surrounding this discovery, epidemics of 
louse-borne relapsing fever (LBRF) devastated populations worldwide (24). Most widespread 
outbreaks of the 20
th
 century were associated with wartime (the World Wars in particular) and 
ensuing conditions of poverty and poor sanitation. In the first half of the century, there were 
millions of cases of relapsing fever in Africa and the Balkans, and the disease caused more than 
5 million deaths in Russia alone (24, 42, 126). Today, epidemic LBRF remains largely confined 
to northeastern Africa. Ethiopia is a focal point of infection and reports approximately 10,000 
cases per year (24). 
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Not attributed to the spirochete until 1904 (133), tick-borne relapsing fever (TBRF) has 
had a more understated, but equally persistent, role in human history as an endemic disease 
regionally affecting most of the world aside from Australia, New Zealand, and Oceania (55). 
Today, TBRF remains a significant human health concern. Its impact is most dramatically felt in 
parts of Africa (Tanzania, Ethiopia, Senegal, Mauritania, and Mali) (41, 45, 82) where it is the 
most common cause of fever, surpassing even malaria, in certain regions (168). In the heavily 
impacted Tanzanian village of Mvumi, TBRF sickens nearly 40% of children less than one year 
of age and is the seventh most frequent cause of childhood mortality (164). Complicating the 
present situation, TBRF is not a reportable disease in many African countries; thus, the current 
epidemiology of this disease is poorly understood. A 2004 study underscored this point by 
revealing that 8.8% of ―fever‖ patients in Togo in fact suffered from TBRF, a disease unknown 
in that country previously (116). TBRF is also endemic to regions of North America, Mexico, 
Central and South America, the Mediterranean, and Central Asia (48). In North America, TBRF 
occurs sporadically west of the Mississippi River in the United States, as well as in southern 
British Columbia, Canada (22, 47, 49, 62, 144, 148, 155, 167). 
 
Etiology and transmission of relapsing fever 
Relapsing fever is caused by at least 15 different Borrelia species (127, 130) that are 
transmitted to humans by arthropod vectors. LBRF is distinguished from other forms of the 
disease by several unique etiological features. It is caused exclusively by the spirochete B. 
recurrentis, and is transmitted by the human body louse, Pediculus humanus humanus (126). 
Infection with LBRF does not occur through bites of feeding arthropods, but rather through 
autoinoculation of abraded skin with infected louse hemolymph and possibly feces (75). Spread 
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of this disease is highly dependent upon human-louse association for several reasons. First, 
LBRF is not a zoonosis; rather, humans act as the sole mammalian host (14). Secondly, because 
transovarial transmission of spirochetes does not occur in lice, the naive louse may become 
infected only through immediate interaction with a spirochetemic human (55). 
In contrast, TBRF is caused by a number of different Borrelial species, including the Old 
World TBRF spirochetes B. duttonii, B. crocidurae, and B. persica, and the North American 
spirochetes B. hermsii and B. turicatae (54, 67). All are transmitted to humans through bites of 
infected argasid Ornithodoros ticks. Because TBRF spirochetes are present in tick salivary 
glands, direct transmission to the host occurs even during the alacritous (20 min-1 hr) 
bloodmeals typical of soft-bodied ticks (143). The bacterium-vector relationship for TBRF 
spirochetes is thought to be highly specific—generally each Borrelia species associates with a 
single vector, and vice versa (e.g., B. crocidurae is transmitted only by O. sonrai, B. turicatae 
only by O. turicata, etc.) (169). Many TBRF vectors are long-lived and capable of transmitting 
infection transovarially, making them efficient Borrelial reservoirs and lessening the ecological 
reliance of many TBRF spirochetes on vertebrate hosts (55). 
TBRF is generally an enzootic disease of which humans are accidental hosts. The 
exception to this is B. duttonii, transmitted by O. moubata, for which no natural hosts other than 
humans have been identified (55). Other animals important in the TBRF enzootic cycle include 
small mammals (particularly rodents), and possibly reptiles, birds, and bats (52, 58, 135, 145, 
147, 162). Cases of relapsing fever in domestic dogs and horses have also been documented 
(129, 146, 171). 
 In North America, TBRF is most often caused by B. hermsii. The tick vector, O. hermsi, 
is primarily encountered in the coniferous, high-elevation forests of the western United States. 
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Pine squirrels (Tamiasciurus spp.)  and chipmunks (Tamias spp.) are important natural hosts for 
B. hermsii, and the majority of human cases occur in individuals vacationing in rustic cabins that 
provide a natural interface with both rodent and tick (25, 46, 148). 
  
Clinical disease  
 Relapsing fever is characterized by recurring episodes of high fever that coincide with the 
occurrence of large numbers of spirochetes in the blood (54).  Manifestations of TBRF and 
LBRF in humans are very similar, although the latter tends to cause more severe disease. After 
an incubation period of 2-18 days, illness begins abruptly with nondescript, flu-like symptoms 
such as fever, headache, myalgia, and arthralgia. Fever (often ≥ 104°F) may be accompanied by 
vomiting, dizziness, or delirium. Tachycardia, hepatomegaly (with or without jaundice), and 
splenomegaly are commonly observed (154). LBRF is sometimes associated with hemorrhagic 
phenomena such as the development of petechiae and/or epistaxis (25-50% of cases). A variety 
of respiratory, cardiac, neurological, and ocular complications occur less commonly (126). 
Without treatment, symptoms persist for 2-7 days until the individual generates an antibody 
response sufficient to cause mass clearance of circulating organisms. This results in liberation of 
bacterial components in the bloodstream and subsequent host release of pro-inflammatory 
cytokines, causing a crisis of rigors, hypotension, and diaphoresis. Cardiovascular collapse 
occasionally results (46), and the majority of deaths occur during this phase of infection. The 
crisis is followed by temporary symptom resolution and spirochetemic relapses of decreasing 
severity.  
Diagnosis is typically made by microscopic observations of spirochetes in the patient’s 
blood (44). However, this method requires that blood be examined during febrile peaks, and even 
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then spirochetes will be present in only about 70% of samples (154). A more sensitive method 
involves recultivation of spirochetes from patients’ blood either in liquid culture or through 
inoculation of susceptible laboratory animals (46, 154). Serological or PCR-based methods are 
occasionally used in research settings or in isolated clinical cases.  
 Treatment of relapsing fever consists of antibiotics (doxycycline, erythromycin, or 
chloramphenical) administered over the course of seven days (44). Antibiotic administration 
often precipitates a Jarisch-Herxheimer reaction (J-HR), which is akin to the crisis phase of 
natural infection and similar to the classic endotoxin reaction. Borrelia lack LPS (see next 
section), but actions of the antigenic variable major proteins (Vsp/Vlp) have been implicated in 
this inflammatory process (149, 170). Within the host, J-HR is associated with increased plasma 
levels of IL-6, IL-8, and TNFα (114), and pre-treating patients with anti-TNFα antibodies has 
been shown to attenuate the reaction’s severity (53).  
Without treatment, case mortality rates range from 4-10% for TBRF and 10-40% for 
LBRF; antibiotic therapy decreases these numbers to <5% (126). Much higher rates of death (up 
to 70% (24)) were documented during past epidemics, likely a result of malnourishment and 
generalized poor health among the affected populations.  
 
Cell structure and genetics 
 The Borrelia are variably sized spirochetes, ranging from 8-30 µm in length and from 
0.2-0.5 µm in width (14). They have a diderm membrane ultrastructure (85) but, unlike 
traditional Gram-negative organisms, lack lipopolysaccharide (LPS) (163). Between the outer 
membrane sheath and the protoplasmic cylinder, Borrelia have a variable number (7-30) of 
periplasmic flagella organized in flat, ribbon-like formations (14, 34). Interactions between the  
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flagella and the cell cylinder confer upon Borrelial spirochetes a distinctive flat-wave 
morphology and translational motion (66). 
The Borrelia have an extremely unusual, fragmented genomic structure consisting of a 
linear chromosome and multiple linear and circular plasmids (10, 14, 16, 56). This unique 
genomic composition, dominated by extrachromosomal elements and covalently-closed linear 
DNA molecules (13, 33), appears to be ubiquitous among both Lyme and RF spirochetes (30, 83, 
92). The linear chromosome of B. burgdorferi type strain B31 has a G+C content of 28.6% and 
bears most housekeeping genes amidst the compactly arranged coding sequences that 
collectively occupy 93% of the chromosome (60). Additional sequencing data have suggested 
that this organization is generally conserved among Borrelia species. In contrast, Borrelial 
plasmid compositions can vary markedly among even isolates of the same species. Events 
associated with this variability include plasmid loss and intragenomic recombination (98, 99, 
142). The latter may occur through homologous or non-homologous recombination events that 
result in gene duplications and truncations, as evidenced by the numerous paralogous genes and 
pseudogenes that have been identified on some circular and most linear plasmids (29, 31, 60). 
Also unusual for bacterial extrachromosomal elements, Borrelial plasmids (including the 
prophage cp32 family) encode a variety of primarily lipoprotein factors essential for infectivity 
and transmission (160). Cp26 carries diverse genes including resT, guaA, guaB, and ospC  (33, 
100) and is uniquely critical to spirochetal survival and in vitro growth. 
Examinations of chromosomal sequences have also revealed that Borrelia retain only 
basic metabolic capabilities, lacking genes for de novo synthesis of amino acids, fatty acids, and 
nucleotides (60). As a result of their minimalist genomes, Borrelia spirochetes are fastidious and 
entirely dependent upon vertebrate or invertebrate hosts (the genus contains no known free-living 
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species). Implications of this in the laboratory context include the requirement for highly 
complex media during cultivation (14).  
 
Pathobiology and immune evasion 
RF spirochetes are predominantly blood-borne pathogens and reach densities in the host 
bloodstream as high as 10
8
 spirochetes per milliliter (54, 154). Within the blood, interactions 
with cellular components may contribute to spirochetal pathogenicity. B. crocidurae, B. duttonii, 
and B. hispanica have been demonstrated to aggregate erythrocytes into spirocentric rosettes via 
interaction with erythrocyte neolacto- glycans (70). The role of this process during infection is 
unknown, but both immune-evasive (26) and disseminative (152) functions have been proposed. 
Additionally, thrombocytopenia is the most common clinical finding of TBRF (47), and the 
interaction of Borrelia spirochetes with human and rodent platelets has been well-documented 
(2, 4, 35, 64). In relapsing fever, formation of spirochete-platelet complexes appears to directly 
induce thrombocytopenia through elevated platelet clearance (4). The precise mechanism of this 
interaction is unknown, as platelet integrin αIIb3 mediates Borrelial attachment in vitro (2, 35) 
but has been demonstrated to be nonessential during infection (4).  
Complications associated with relapsing fever, including neuroborreliosis, arthritis, and 
carditis, reflect the pathogen’s ability to disseminate extravascularly (27, 65, 94, 117, 151). 
Studies have suggested that, like the closely-related Lyme disease Borrelia, relapsing fever 
spirochetes display tropism for brain and collagenous tissues (28), and that specific tissue 
tropism may be serotype-dependent (94, 109, 150). In addition to causing direct tissue damage, 
low-level extravascular persistence may contribute to disease reactivation following immune 
system compromise (90) or co-infection (e.g., with malaria) (96).  
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Dissemination from circulating blood involves passage across tissue barriers such as the 
extracellular matrix and the vascular basement membrane. Recruitment of host-derived 
plasminogen (zymogen of the serine protease plasmin) has been demonstrated in both Lyme and 
relapsing fever Borrelia (63, 69, 81, 88, 134, 141). In Borrelia burgdorferi, plasminogen binding 
enhances penetration of endothelial monolayers in vitro (38, 68), while, for RF spirochetes, 
plasminogen has been shown to play an important role in heart, kidney, and brain invasion (65, 
117).  
 Host clearance of RF spirochetes is achieved through an IgM-mediated, T cell-
independent immune response in which the B1b B cell subclass appears to play a central role (3, 
11, 40, 115). This adaptive immune response, although efficacious and rapid, is serotype-
specific. Therefore, to evade antibody-mediated immunity, RF Borrelia employ a prototypical 
antigenic variation system involving variable major lipoproteins Vsp and Vlp (9, 15, 161). This 
system is founded on multiple silent (―archived‖) versions of  vlp and vsp genes scattered 
throughout genomic linear plasmids; 59 vlp/vsp alleles have been identified (43). A single 
expression locus for these genes resides near the telomere of a 28-kb linear plasmid, into which 
any one of the silent genes may be copied, in its entirety, through non-reciprocal recombination. 
Specific upstream and downstream homology sequences appear to mediate this recombination 
and to dictate an observed hierarchy of switch rates between variants (12). Serotypic variants 
spontaneously arise, both in vivo and in culture, at a frequency of 10
-4
-10
-3
 events per cell per 
generation (119).  
Innate immunity appears to play a role in controlling Borrelial infections (20), although 
the mechanisms remain poorly defined. The ability of RF Borrelia to functionally evade innate 
immunity, however, is clearly demonstrated by the massive and sustained bacteremia caused by 
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these organisms. Many pathogens exploit host complement regulatory processes as a means of 
innate immune evasion, usually through production and/or recruitment of factors that negatively 
regulate the complement cascade (6, 18, 19, 61, 74, 112, 113, 118, 123, 125, 128, 140, 165). 
These mechanisms have been documented in many pathogenic spirochetes including Leptospira 
species (8, 159), Treponemes (103, 104), and Lyme and relapsing fever Borrelia.     
 
Complement and factor H  
 The complement system is comprised of  more than 30 soluble and cell-surface proteins 
that act in concert to eliminate pathogens by opsonization and lytic events. Many complement 
proteins exist in the body as zymogens that are sequentially activated through a cascade of  
cleavage reactions. Such activation can occur by way of three pathways (classical, lectin, and 
alternative) that differ in their mechanisms of initiation but ultimately converge in the terminal 
stages of activity (72, 138).  
 Both the classical and the lectin pathway are activated by distinct recognition 
mechanisms including, for the former, antigen-complexed antibodies, and, for the latter, specific 
cell-surface arrangements of mannose residues. In contrast, low-level activation of the alternative 
pathway occurs independently and spontaneously in the plasma. This process results in local 
pools of activated C3b that bind carbohydrates and proteins on nearby cell surfaces via exposed, 
highly reactive thioester bonds  (120). If binding fails to occur, C3b is quickly inactivated by 
hydrolysis (172). Upon binding to an activating surface (e.g., a pathogen), C3b is bound by 
zymogen factor B, which is itself cleaved and activated by factor D. The large Bb fragment 
remains in association with C3b, forming the alternative pathway C3 convertase, C3bBb. Both 
the classical and the lectin pathway lead to the generation of functional equivalents of this 
9
enzyme; therefore, the pathways converge at this stage. The C3 convertase generates high local 
levels of active C3b fragments, which act independently as opsonins or complex with the C3 
convertase to form the C5 convertase (for the alternative pathway, C3b2Bb) (173). This enzyme 
cleaves and activates C5, generating C5a, a potent anaphylatoxin, and C5b, the earliest 
membrane attack complex (MAC) component. During MAC formation, the terminal complement 
components assemble as follows: C5b binds C6 and C7 which, in complex, undergo 
conformational changes and insert into the pathogen cell membrane via a hydrophobic region on 
C7. This allows C8 to bind, insert into the membrane, and induce the final component, C9, to 
bind and polymerize. The resulting pore-like structure is cytolytic and promotes elimination of 
target cells (138).     
The complement cascade is tightly regulated by a variety of cell-surface and fluid-phase 
proteins to prevent uncontrolled or inappropriate activation within the host (175). Factor H (FH) 
is the major fluid-phase regulator of the alternative complement pathway.  A plasma protein of 
155 kDa, human FH is composed of individually folding domains known as short consensus 
repeats (SCR) which are joined by short, flexible linking sequences (139). Domain conformation 
is maintained by disulfide bonds that form in a 1-3 and 2-4 manner between four conserved 
cysteine residues harbored within each SCR. A critical element of alternative pathway regulation 
involves specific discrimination between self-cells and pathogens targeted for destruction. This 
specificity is largely conferred by FH, which contains multiple heparin-binding sites that interact 
with polyanionic regions present on  human cells and tissues (but generally absent from 
microbial surfaces), such as glycosaminoglycans (GAGs) and sialic acid residues. The most 
well-characterized heparin-binding sites are contained within SCRs 7 and 20, and an additional 
site is present within SCRs 9-15 (57, 139, 140, 176). Interactions with such polyanionic surfaces 
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enhance the binding affinity of FH for C3b (111) and allow FH to inhibit cascade progression by 
several mechanisms, including cofactor activity in the factor-I mediated cleavage of C3 and 
destabilization of the C3 convertase (172).  
 
Borrelial factor H binding and FhbA  
As discussed, many pathogenic spirochetes exploit the protective capacity of exogenous 
FH by recruiting it to surface-expressed proteins during host infection. This process has been 
most extensively examined in the LD species B. burgdorferi, which produces five factor H-
binding proteins (FHBPs) including CspA (BBA68/CRASP-1); CspZ (BBH06/CRASP-2); and 
OspE family proteins BBN38, BBL39, and BBP38 (CRASP3-5, respectively) (1, 23, 73, 80, 102, 
107). Other Borrelial species that produce FHBPs include LD spirochete B. afzelli and RF 
spirochetes B. recurrentis, B. parkeri, and B. hermsii (69, 78, 108, 141). Among the RF species, 
the FH-binding mechanism of B. hermsii and its single FHBP, factor H-binding protein A 
(FhbA), are most well characterized. 
 FhbA is a ~20-kDa outer surface lipoprotein that is encoded by a single copy gene borne 
on the 200-kb linear plasmid lp200 (78). Production of FhbA is widespread among low-passage 
B. hermsii isolates; however, several high-passage strains (RENHP, FROHP, CONHP) have been 
found to lack the fhbA gene and lp200, and rather to harbor a 170-kb linear plasmid. This change 
is consistent with the linear plasmid rearrangement frequently observed in Borrelia, and also 
suggestive that fhbA may be of prophage origin. Two phyletic fhbA groups (fhbA1, fhbA2) have 
been identified (79) and correlate well with B. hermsii genomic group (GG) designations 
previously established through sequence analyses of chromosomal loci (flab, glpQ, and gyrB) 
(122). FhbA is expressed during infection and has been demonstrated to be highly immunogenic 
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(39, 76, 78, 79). In addition to FH, FhbA binds other serum proteins including FHL-1 (a FH 
splice variant with complement regulatory and adhesive functions) and plasminogen (77).  
FH binding is essential to complement resistance in the spirochete Treponema denticola 
(101). In the Borrelia, evidence supports the notion that FH-binding ability is linked to resistance 
to complement-mediated killing in vitro and during infection (23, 76, 86, 108, 131). However, 
direct demonstration of the role of FH binding in the Borrelial disease process, achieved 
traditionally through gene inactivation, has not yet been possible.  
 
Genetic manipulation of relapsing fever spirochetes 
 The first demonstration of genetic manipulation of a Borrelia species was in the Lyme 
disease spirochete B. burgdorferi (136). Although applications of Borrelial molecular genetics 
have broadened considerably, the same basic methods are still largely observed (132). While 
standard techniques are employed to introduce DNA by electroporation, large amounts of DNA 
are required to overcome the Borrelia’s notoriously low transformation efficiency (166). An 
important and confounding factor in the genetic manipulation of B. burgdorferi is 
transformation-associated loss of endogenous plasmids that encode proteins required for survival 
in either tick or mammalian hosts (91, 124, 132).  
To date, there is only a single report of site-directed allelic exchange in a RF Borrelia 
species (17) and diverse tools for this purpose are lacking. Although chromosome sequences of 
B. hermsii (GGI DAH isolate), B. turicatae, B. recurrentis, and B. duttonii (92) are now 
available, assembled, annotated, and complete sequences for plasmid components of these 
genomes have not yet been determined. 
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Research objectives 
 Prior to clearance by serotype-specific, antibody-mediated adaptive immune processes, 
RF spirochetes persist at extremely high levels in the host bloodstream (154). This high-level 
bacteremia suggests facilitation by spirochetal mechanisms of innate immune evasion. One such 
putative mechanism involves recruitment of host-derived factors that negatively regulate the 
complement cascade. Binding of FH, the primary fluid-phase regulator of the alternative 
complement pathway, has been demonstrated in a variety of pathogens including Borrelia 
species (61, 74, 112, 113, 140). TBRF spirochete B. hermsii binds FH via its FhbA protein (78). 
However, direct demonstration of the role of FhbA in the disease process has been precluded by 
the lack of a reliable genetic manipulation system for RF Borrelia. In an effort to develop 
molecular tools for this purpose while exploring the role of FH binding in Borrelial virulence, 
this work addresses the following aims: 
 
1. Expand the genetic tools available for studying the molecular pathogenesis of RF 
spirochetes 
 Molecular characterization of TBRF spirochete B. hermsii has been hindered by 
methodological challenges; this objective will involve refining existing techniques to 
overcome these challenges. Site-specific allelic exchange mutagenesis and a unique 
kanamycin resistance-green fluorescent protein construct will be utilized to achieve 
genetic transformation of B. hermsii strain YOR.  Resulting transformant clones will 
be characterized both in vivo and in vitro. 
 
2. Directly assess the role of FH binding in the virulence of TBRF Borrelia  
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Using genetic transformation techniques, a B. hermsii strain YOR fhbA deletion 
mutant will be generated. Analyses of the interaction of this strain with 
complement proteins will clarify the importance of FhbA expression in FH 
binding and in vitro complement inactivation. Infection and serum sensitivity 
assays will be used to assess the role of the FH-binding phenotype in innate 
immune evasion by TBRF spirochetes.  
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Materials and Methods 
 
Bacterial strains and cultivation 
 Borrelia hermsii strain YOR was isolated in 1964 from a human relapsing fever patient 
in Siskiyou County, California (122). Borrelia andersonii isolate MOD-1 was originally isolated 
from nymphal Ixodes dentatus ticks in Bollinger County, Missouri (93) (Table 1). B. hermsii and 
B. andersonii were cultivated in BSK-H complete media supplemented with 12% and 6% rabbit 
serum, respectively, at 37°C in a humidified atmosphere with 5% CO2. Antibiotic selection of 
transformant strains was achieved with kanamycin (200 μg ml-1). 
 
Isolation of genomic DNA 
 Cells from log-phase cultures of wild type B. hermsii strain YOR were collected by 
centrifugation (14,000 x g, 15 min, 4°C) and washed twice with phosphate buffered saline (PBS) 
(1.37 M NaCl, 27 mM KCl, 100 mM Na2HPO4, 20 mM KH2PO4, pH 7.4). Cells were then 
resuspended in TES (50 mM Tris-HCl, pH 8.0; 40 mM EDTA; 25% sucrose) and lysed through 
incubation with SDS (2%) and Proteinase K (0.3 mg ml
-1
) (37°C, 45 minutes). Liquid-liquid 
extraction of DNA was performed using phenol/chloroform/isoamyl alcohol (25:24:1) and 
centrifugal phase separation. Upon aqueous phase recovery, DNA was precipitated by the 
addition of 3 volumes of cold 100% ethanol and 0.1 volume of 3 M sodium acetate (pH 5.2) (30 
minutes, -70°C). DNA was collected by centrifugation (14,000 x g, 5 min, 4°C), washed twice 
with 70% ethanol, and allowed to air dry at room temperature. DNA was then incubated in TE  
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Table 1. Summary of strains used in this study 
 
Strain or Isolate   Source    Comments 
 
B. hermsii YOR   Human, Siskiyou Co.,      Wild type strain       
(Bh YOR-wt)   CA (122)      
      
 
Bh YOR::kan
r
gfp  This study   B. hermsii YOR transformant;  
        bears kan
r
gfp insertion  
      
 
Bh YORΔfhbA   This study   B. hermsii YOR transformant; 
        bears kan
r
gfp insertion and  
        fhbA gene deletion  
 
B. andersonii MOD-1  Ixodes dentatus tick,   Wild type isolate, 
    Bollinger Co., MO (93)  Non-FH-binding 
         (Marconi, R.T.,  
        unpublished data) 
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(10 mM Tris-HCl, pH 8.0; 1 mM EDTA) with RNase (Abgene; 0.03 mg ml
-1
), 1% SDS, and 
Proteinase K (0.3 mg ml
-1
) for 1 hour at 37°C;  extracted and precipitated once again, as above; 
and resuspended in water. Quantification was achieved by spectrophotometric measurement of 
UV absorbance (A260/A280). 
  
Polymerase chain reaction 
 Polymerase chain reaction (PCR) was performed using an S1000 Thermal Cycler (Bio-
Rad) and template sources that included genomic DNA, plasmid DNA, and bacterial cells. 
Preparation of cellular template consisted of collecting and boiling Borrelia cells in water (98°C, 
12 minutes), and, following brief centrifugation to remove cellular debris, utilization of 
supernatants at 1 μl reaction-1. Genomic and plasmid DNA templates were used at 5.0 and 0.5 ng 
reaction
-1
, respectively. The final volume of each PCR reaction was 20 μl, and primers (Table 2) 
were used at constant 15-μM concentrations. For vector construction, Phusion High-Fidelity 
Master Mix (Phusion High-Fidelity DNA polymerase (0.02 U µl
-1
), 200 µm each dNTP, 1.5 mM 
MgCl2; New England BioLabs) was used. Phusion-specific cycling conditions were as follows: 
98°C, 30 seconds; (98°C, 10 seconds; 60°C, 10 seconds; 72°C, 30 seconds-1.5 minutes) x 35 
cycles; 72°C, 5 minutes. All other PCR applications were performed using GoTaq Green Master 
Mix (GoTaq DNA polymerase, 200 µm each dNTP, 1.5 mM MgCl2; Promega) and the following 
cycling conditions: 94°C, 2 minutes; (94°C, 30 seconds; 53-63.5°C, 30 seconds; 72°C, 30 
seconds-2 minutes) x 35 cycles; 72°C, 5 minutes. Amplicons were analyzed by agarose gel 
electrophoresis and ethidium bromide staining.  
 
Vector construction  
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A suicide vector, designated pFAEV3, was designed to allow stable integration of a 
kanamycin resistance (kan
r
) cassette and gfp into lp200. The integration site consists of a 209-bp 
non-coding region residing between the 3' end of fhbA and the 3' end of an oppositely-oriented 
hypothetical open reading frame (labeled as ORF dn in Figure 1). Regions of lp200 and gfp and 
kan
r
 genes were PCR-amplified from B. hermsii YOR genomic DNA and previously constructed 
plasmids as described below. Primers were tailed with appropriate restriction sites as needed to 
allow for subsequent cloning procedures (Table 2). First, a 1582-bp region of lp200 was 
amplified from genomic DNA using the VC1 and VC2 primers. This amplicon extends from 
upstream of fhbA through its stop codon (encompassing the fhbA gene and an upstream 
hypothetical ORF; VC2 harbors an NheI site). The 209-bp non-coding region targeted for 
insertion was amplified from genomic DNA in two fragments: (i) the 99-bp region immediately 
3' of fhbA, using VC3 and VC4 primers (with NheI and SalI restriction sites, respectively), and 
(ii) a 625-bp region encompassing the remaining non-coding sequence and a downstream ORF 
of unknown function, using VC9 and VC10 primers (with AatII and MluI restriction sites, 
respectively). The kan
r
 gene, linked to the constitutively active B. hermsii DAH flgB promoter 
(PflgB-kan
r
), was amplified from pTABhFlgB-Kan (17) (kindly provided by Dr. T. Schwan) 
using the VC5 and VC6 primers (with SalI and AscI restriction sites, respectively). gfp was 
amplified from pCE320 (51) (kindly provided by Dr. J. Radolf) using the VC7 and VC8 primers 
(with AscI and AatII sites, respectively). The kan
r
 and gfp genes were linked to allow for 
expression from the kan
r
 cassette. The two genes are separated by 60 bp of sequence derived 
from the region upstream of the gfp gene. All amplicons were cut with the appropriate restriction 
enzymes (New England Biolabs) and, using standard subcloning techniques, ligated into a 
pCR2.1 TOPO backbone (Invitrogen) to yield pFAEV3 (Figure 1A).  
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Generation of a B. hermsii YOR fhbA deletion mutant was achieved through allelic 
exchange mutagenesis using suicide vector construct pFAEV3ΔfhbA. This vector was derived 
from pFAEV3, described above. To construct pFAEV3ΔfhbA, the pFAEV3 vector was subjected 
to digestion with NheI, resulting in excision of the coding region of fhbA from the vector 
sequence. The construct was then re-ligated to yield the final pFAEV3ΔfhbA vector (Figure 1B). 
 
Transformation of B. hermsii 
 Plasmids were propagated in NovaBlue Escherichia coli cells (Novagen), purified 
(HiSpeed Plasmid Midi Kit; Qiagen) according to manufacturer’s instructions, and linearized 
with AhdI and PflfI prior to transformation. Electroporation conditions were adapted from 
methods originally developed by Samuels et al. for B. burgdorferi (136). B. hermsii YOR cells 
were harvested from a 100-ml, mid-log phase culture by centrifugation (5000 x g, 20 min, 4°C), 
washed 3 times with cold EPS buffer (93 mg ml
-1
 sucrose, 15% glycerol), and suspended in 100 
μl EPS buffer containing 25 μg of linearized pFAEV3 or pFAEV3ΔfhbA vector. After 5 min on 
ice, the cells were electroporated (0.2 cm cuvette, 2.5 kV, 25 mF, 200 W), transferred to 10 ml of 
BSK-H media with 12% rabbit serum, and incubated for 24 hours at 37°C. The culture volumes 
were increased to 50 ml with fresh BSK-H medium and supplemented with kanamycin (200 μg 
ml
-1
). Cultures were maintained at 37°C and growth was monitored by darkfield microscopy.   
Transformant clones were isolated through limiting dilution. Sequential dilutions 
containing, theoretically, 50 to 0.00064 spirochetes were prepared and cultured in sterile 96-well 
tissue culture plates (Becton Dickinson) containing 200 μl BSK-H media with 200 μg ml-1 
kanamycin per well. These plates were then sealed with adhesive plate covers (EdgeBio) and 
incubated at 37°C (5% CO2). Growth was monitored by darkfield microscopy.  
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Figure 1. B. hermsii pFAEV3 and pFAEV3ÄfhbA suicide vector maps. Suicide vector 
pFAEV3 was constructed to allow for the introduction of a selectable marker (kanr) and 
green fluorescent protein (gfp) into a non-coding region of the native B. hermsii linear 
plasmid, lp200. The vector map is depicted in Panel A. The primers used to generate the 
amplicons for vector construction (VC) are indicated (listed in Table 2). (B) B. hermsii 
fhbA deletion vector (pFAEV3ÄfhbA) was derived from pFAEV3, through NheI 
digestion, to permit kanrgfp cassette integration and deletion of the fhbA coding region 
from lp200.  
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Table 2. Oligonucleotide primers 
 
Primer  Sequence (5' to 3') 
VC1  GTCAATGGTATATTAGTTTCAAGTTCTATGACCC 
VC2  ACGCGTAAAGTCGACTTAACATATAAATAATACTGATATTAAAATTTATGTAAA 
VC3  GCTAGCGTTGATCTTATAAATCAAACTGATGTAAAATCAAAACC 
VC4  GTCGACTTAACATATAAATAATACTGATATTAAAATTTATGTAAA 
VC5  GTCGACGTTAAAGAAAATTGAAATAAACTTGGACTATGTTAATG 
VC6  GGCGCGCCTTAGAAAAACTCATCGAGCATCAAATG 
VC7  GGCGCGCCGGGCGAATTCGGCTTATTCC 
VC8  GACGTCCTATTTGTATAGTTCATCCATGCCATGTG 
VC9  GACGTCCCTGAGAGTATAGGCAGTACTTCAATTACTACC 
VC10  ACGCGTCAATTGATATTGATGTGGCGTTGATTTCTAAAATAG  
TC1  GTCTACTCTATCTGGGATACTAAAGAGC 
TC2  TGTGATTTATTCAATAAAAACAAAAAATTAGATGC 
TC3  TTAAGTTTTTAAATATTCCATTATAGTTTCAAAAAAATTGTC 
TC4  GAGGCATAAATTCCGTCAGC 
TC5  GTCCACACAATCTGCCCTTTC 
TC6  GCATTAAGTAAGCGGTTTGTGAGC 
F1  ATCAGTGAGCTCGATTTATTCAATAAAAACAAAAAATTAGATGCTGATTTAC 
F2  TGATACCTCGAGTTAAGTTTTTAAATATTCCATTATAGTTTCAAAAAAATTG 
 
Abbreviations used in primer designations are as follows: VC=vector construction; 
TC=transformation confirmation. Restriction site/sacrificial base tails are indicated by 
underlining.  
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Growth curve analyses  
To assess growth rates, equal numbers of actively growing cells of each B. hermsii YOR 
strain were inoculated into fresh medium and maintained at 37°C. Microscopic cell counts of 
each culture were conducted daily for seven days (from ten fields under 400X magnification, 
using darkfield microscopy) and the average numbers of spirochetes per field of view were 
determined at each time point. 
 
Plasmid analysis by pulsed-field gel electrophoresis  
Cells from log-phase cultures were collected by centrifugation (6,000 x g, 15 min, 4°C), 
washed twice with PBS, and resuspended in TN buffer (50 mM Tris-HCl, pH 8.0; 150 mM 
NaCl) to a density of ~1 x 10
9
 cells ml
-1
. Cell suspensions were warmed to 37°C then mixed with 
an equal volume of 1.2% agarose (InCert; FMC). Agarose-cell mixtures were transferred to plug 
casters and allowed to solidify at room temperature. To lyse embedded cells, plugs were 
sequentially incubated in PK solution (50 mM Tris-HCl, pH 8.0; 50 mM EDTA; 1.5% SDS; 1 
mg ml
-1
 Proteinase K) at 45°C, and TE* wash (10 mM Tris-HCl, pH 8.0; 10 mM EDTA) at 
50°C. Plugs were then loaded in 1% agarose gels (SeaKem Gold; Lonza) prepared with 0.5x 
TBE buffer (44.5 mM Tris base; 44.5 mM boric acid; 1 mM EDTA, pH 8.0). Electrophoresis 
was performed in 0.5x TBE buffer at 14°C using a contour-clamped homogeneous electric field 
(CHEF) mapper system (Bio-Rad). Automatic parameters for separation of DNA molecules 
between 5 and 200 kb were utilized (calibration factor, 1.00; gradient, 6.0 V/cm; run time, 15:16; 
included angle, 120°; initial switch time, 0.22 s; final switch time, 17.33 s; ramping factor, 
a=linear). DNA was visualized by ethidium bromide staining. 
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Immunoblot analyses  
B. hermsii cells were solubilized in reducing sample buffer (0.25 M Tris-HCl, pH 8.0; 4% 
SDS; 2% β-mercaptoethanol; 20% glycerol; 0.001% bromophenol blue), fractionated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (200 V, 60 minutes) in 15% 
Criterion Tris-HCl precast gels (Bio-Rad), and transferred to polyvinylidene diflouride (PVDF) 
by electroblotting (100V, 60 minutes). Immunoblots were blocked in blocking buffer (PBS, 0.2% 
Tween 20, 5% nonfat dry milk) for 1 hour, then incubated with primary antibody. Primary 
antibodies included mouse anti-FhbA antiserum (1:1000) and mouse anti-FlaB antiserum 
(1:400,000), diluted in blocking buffer as indicated. Horseradish peroxidase (HRP)-conjugated 
goat anti-mouse immunoglobulin G (IgG) (1:40,000; Pierce) served as the secondary antibody. 
Incubations were performed at room temperature for 1 hour, and were followed each time by 
PBS-0.2% Tween 20 (PBS-T) wash steps to remove unbound antibody. Detection was based on 
the reaction of the HRP conjugate with SuperSignal West Pico chemiluminescent substrate 
(Pierce).  
 
Proteinase K digestion of surface proteins 
 Cells (~3.5 x 10
8
) from log-phase B. hermsii cultures were collected by centrifugation 
(5,000 x g, 20 min, 4°C), washed with PBS, and resuspended in PBS with or without Proteinase 
K (0.2 mg ml
-1
). After 1 hour at room temperature, digestion was inhibited by the addition of 
phenylmethanesulfonylfluoride (PMSF) (5 ug ml
-1
). Cells were collected by centrifugation 
(14,000 x g, 10 min, room temperature) and subjected to immunoblot analysis, as described 
above, to assess FhbA expression at the cell surface. Blots were also screened with anti-FlaB (a 
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constitutively expressed flagellar protein) to demonstrate specific digestion of surface-exposed 
proteins and to confirm equal sample loading. 
 
Affinity ligand binding immunoblot (ALBI) assays  
 B. hermsii cell lysates were fractionated by SDS-PAGE under reducing conditions and 
transferred to PVDF as described above. After blocking, immunoblots were incubated with 
purified human FH (5 ng μl-1; CompTech) in blocking buffer for 1 hour at room temperature, 
then washed with PBS-T. Bound FH was detected with goat anti-human FH antiserum (1:1000; 
Calbiochem) followed by HRP-conjugated rabbit anti-goat IgG (1:40,000; Pierce). Incubations 
were performed in blocking buffer at room temperature for 1 hour, and blots were washed 
between incubation steps. Detection was based on chemiluminescence. 
 
Whole-cell adsorption of FH and IFA 
To assess binding of FH by intact spirochetes, whole-cell FH adsorption assays were 
performed. Cells were harvested from 5-ml, mid-log phase cultures by centrifugation (5000 x g, 
10 min, 4°C), washed with cold PBS, and resuspended in 100 μl PBS (supplemented with 1 mM 
MgCl and 0.15 mM CaCl). The cell suspensions were then incubated with purified human FH 
(0.525 mg ml
-1
) for 1 hour at room temperature. Following extensive washing with PBS, cells 
were recovered by centrifugation (3000 x g, 10 min, room temperature) and FH adsorption was 
assessed by both immunoblot analysis and immunofluorescence assay (IFA). Immunoblot 
analyses were performed as described above: First, cells were solubilized in reducing sample 
buffer, fractionated by SDS-PAGE, and transferred to PVDF. The immunoblots were then 
blocked and screened with goat anti-human FH antiserum (1:1000) followed by HRP-conjugated 
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rabbit anti-goat IgG (1:40,000). Washing was performed between each step, and detection was 
achieved through chemiluminescence. For IFA, cells, adjusted to a density of ~7.0 x 10
6
 ml
-1
 in 
PBS, were spotted onto slides (Superfrost Plus; Fisher) and allowed to dry. The slide-
immobilized cells were blocked with 3% bovine serum albumin (BSA) in PBS-T, then probed 
with goat anti-human FH antiserum at a dilution of 1:5000. The slides were washed three times 
with PBS-T, then incubated with Alexa Fluor 568-conjugated rabbit anti-goat IgG (1:200; 
Invitrogen). All antisera were diluted in PBS-T with 3% BSA, and incubations were performed 
in darkened, humidified chambers for 1 hour at room temperature. After a final wash step, cover 
slips were mounted using an antifade reagent (ProLong Gold; Invitrogen), and the immobilized 
cells were visualized by fluorescence microscopy.  
 
Plasminogen binding assay and ELISA  
Cells from actively growing cultures of each B. hermsii strain were collected by 
centrifugation (5000 x g, 15 min, 4°C) and washed with PBS. Cells were suspended in carbonate 
coating buffer (27.6 mM sodium carbonate, 18.9 mM sodium bicarbonate, pH 9.6) to an adjusted 
concentration of ~1 x10
8
 cells ml
-1
, then incubated in 96-well ELISA plates (Costar 3590; 
Corning) at 100 μl well-1 overnight at 4°C. Plate-immobilized cells were blocked with 5% BSA 
in PBS-T, then incubated with plasminogen (10 μg ml-1 in 5% BSA-PBS-T; Sigma) for 1 hour at 
room temperature. Control wells were (i) coated with wild type B. hermsii YOR cells and 
incubated with 5% BSA-PBS-T only, and (ii) left uncoated, then blocked and incubated with 
plasminogen. To remove unbound plasminogen, plates were washed three times with PBS-T 
using an automated ELx405 Microplate Washer (Bio-Tek). To assess plasminogen binding by 
enzyme-linked immunosorbent assay (ELISA), plates were screened with goat anti-plasminogen 
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antiserum (1:1000) and then washed as above. Bound primary antibodies were detected with 
HRP-conjugated rabbit anti-goat IgG (1:40,000) and 2,2'-azino-bis(3-ethylbenzthiazoline-6-
sulphonic acid) (ABTS) chromogenic substrate. All incubations were performed in 5% BSA-
PBS-T for 1 hour at room temperature. Absorbance was read at 405 nm using an ELISA plate 
reader (ELx808; Bio-Tek). 
 
C3b cleavage assay 
 To assess the role of FH binding in C3b inactivation by B. hermsii, cells (1 x 10
8
) of 
each B. hermsii strain were harvested from mid-log phase cultures by centrifugation (3000 x g, 
15 min, 4°C). Cells were washed with cold PBS, suspended in PBS (with 10mM MgCl2) (50 μl), 
and incubated with or without purified human FH (2 μg ml-1; 37°C; 1 hour). After thorough 
washing, cells were incubated in PBS (with 10mM MgCl2) (20 μl) with purified factor I (150 ng; 
Calbiochem) and C3b (250 ng; CompTech) for 2 hours at 37°C. As a control, FH (100 ng), FI 
(150 ng), and C3b (250 ng) were co-incubated in solution. Following sedimentation of cells, 
reaction supernatants were mixed with reducing sample buffer, fractionated by SDS-PAGE, and 
blotted as described above. The presence of C3b cleavage products was assessed by immunoblot 
analysis using goat anti-human C3 antiserum (1:800; CompTech), HRP-conjugated rabbit anti-
goat IgG (1:40,000), and chemiluminescence. 
 
Serum sensitivity assay 
Aliquots of log-phase cultures of B. hermsii strains and B. andersonii isolate MOD-1 (a 
serum sensitive control) were incubated at 37°C in 50% normal human serum (NHS) (Valley 
Biomedical) or heat-inactivated (56°C, 30 minutes) human serum (hiNHS). After 2, 6, and 24 
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hours, cells were stained using the LIVE/DEAD BacLight Bacterial Viability Kit (Invitrogen) 
according to manufacturer’s instructions, and examined by fluorescence microscopy (ten fields, 
400X magnification) to assess survival. Data are presented as percent survival, calculated as: 
[number alive/(number alive + number dead)] x 100. 
 
Cell-surface deposition of C9 
 Cells (1 x 10
6
) from mid-log phase cultures of B. hermsii YOR strains and B. andersonii 
isolate MOD-1 were collected by centrifugation (5000 x g, 15 min, 4°C), washed with cold PBS, 
and incubated in 10% NHS or hiNHS for 30 min at 37°C. Following extensive washing, cells 
were immobilized onto ELISA plates in carbonate coating buffer as described above and 
screened with goat anti-C9  antiserum (1:1000; CompTech) and HRP-conjugated rabbit anti-goat 
IgG (1:40,000). Detection was achieved using ABTS chromogenic substrate. Blocking and 
incubations were performed in 1% BSA-PBS-T. All other ELISA conditions were as described 
above. 
 
Infection analyses  
Infectivity was assessed by subcutaneous needle inoculation of C3H/HeJ mice (n=5) with 
5 x 10
4
 spirochetes in BSK-H media. One uninfected mouse of the same cohort was maintained 
as a control. Blood samples were collected from tail nicks performed 0, 3, 4, 7, 10, 14, 18, and 
42 days post-infection and were mixed with sodium citrate buffer (0.15 M trisodium citrate in 
water) at a 9:1 ratio to prevent clotting. The presence of spirochetes at each time point (with the 
exception of Day 42) was assessed visually by darkfield microscopy of diluted blood samples 
(1:20 in PBS; 5 μl). Data are presented as number of spirochetes ml-1 blood, calculated using the 
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following conversion factor: number of spirochetes 400X field
-1
 x (2.5 x 10
3
) = number of 
spirochetes ml
-1
. Additionally, at each time point, undiluted blood (6 μl) was added to BSK-H 
media (supplemented with rifampicin, fosfomycin, and amphotericin B) and incubated at 37°C. 
Cultures were microscopically assessed for spirochete growth after 3 weeks of incubation. 
 
Serological analyses and generation of recombinant protein 
Blood was collected at 4 weeks post-inoculation and serum (―infection serum‖) was 
harvested using standard centrifugal methods. To assess murine seroconversion, ELISA plates 
were coated with a suspension of wild type B. hermsii YOR cells in carbonate buffer, as 
described above. Plates were blocked with 1% BSA-PBS-T and wells were screened in triplicate 
with a dilution series (from 1:50 to 1:109,350) of infection serum from each mouse. After 
washing, bound anti-Borrelia IgG was detected using HRP-conjugated goat anti-mouse IgG 
(1:20,000) and ABTS chromogenic substrate. Incubations were performed in 1% BSA-PBS-T. 
All other ELISA conditions were as described above. 
To determine whether sera of infected mice was reactive against FhbA, recombinant B. 
hermsii YOR FhbA (r-FhbA) was generated, immunoblotted as described above, and screened 
with infection sera (pooled by experimental group; 1:2500). Detection was achieved using goat 
anti-mouse IgG (1:40,000) and chemiluminescence. To generate the r-FhbA protein utilized in 
this assay, the coding sequence of fhbA (exclusive of the signal sequence) was PCR-amplified 
from B. hermsii YOR genomic DNA using primers tailed by restriction sites compatible with 
subsequent cloning steps (F1 and F2; Table 2). Amplicons were gel purified (QIAquick Gel 
Extraction Kit; Qiagen), digested with SacI and XhoI, and ligated into the pET45b(+) vector 
(Novagen) through standard methods. The resulting plasmids were propagated according to 
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manufacturer’s instructions in NovaBlue and BL21 (DE3) E. coli cells (Novagen). Following 
IPTG induction, recombinant proteins, bearing 1.7 kDa N-terminal His-Tags, were purified from 
E. coli cell lysates using a His-Bind purification kit (Novagen) as directed by the manufacturer.  
 
Microscopy  
 All microscopy was performed using an Olympus BX51 microscope fitted with a DP71 
camera (Olympus) and fluorescein and rhodamine filter sets. Darkfield and fluorescence 
micrographs were recorded using DP Controller 3.1.1.267 software (Olympus). 
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Results 
 
Generation of B. hermsii YOR transformants 
 To generate a B. hermsii strain that harbors a selectable marker (kan
r
) and constitutively 
expresses a fluorescent marker (gfp) (Bh YOR::kan
r
gfp), the pFAEV3 vector was constructed 
(Figure 1A) and electroporated into B. hermsii YOR. Transformation resulted in the insertion of 
a kan
r
-gfp cassette into a non-coding sequence located on lp200 between the wild type fhbA gene 
and a hypothetical ORF (Figure 2A). The B. hermsii YOR fhbA deletion mutant (Bh YORΔfhbA) 
was generated using the pFAEV3ΔfhbA vector (Figure 1B), which mediated deletion of the fhbA 
coding region from lp200 and integration of the kan
r
-gfp cassette as described above (Figure 
2A). Clonal populations of Bh YOR::kan
r
gfp and Bh YORΔfhbA were derived through limiting 
dilution. 
PCR analyses (Figure 2A) and fluorescence microscopy (Figure 2B) were performed to 
verify successful transformation. All transformant spirochetes observed by fluorescence 
microscopy produced GFP, although some cell-to-cell variability in signal intensity was 
observed (data not shown).  
 
Characterization of plasmid composition and growth kinetics 
Electroporation of B. burgdorferi often results in the loss of some plasmids (91, 124, 
132). Since Borrelia plasmids encode genes required for survival in mammalian and arthropod 
hosts, plasmid loss can influence the interpretation of mutagenesis studies. To determine if  
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Figure 2. PCR- and microscopy-based verification of allelic exchange. Panel A 
presents a schematic depicting lp200 from wild type B. hermsii YOR (Bh YOR-wt) and B. 
hermsii transformant strains (Bh YOR::kanrgfp, Bh YORÄfhbA) after mutagenesis. 
Locations of primer targets for PCR used to confirm transformation (TC primers) are 
indicated. The ethidium bromide-stained amplicons obtained through PCR analyses are 
shown. Primer sequences can be found in Table 2. (B) Fluorescence microscopy (FM) 
was performed to screen strains for GFP production during in vitro culture. Darkfield 
microscopy (DM) was used to confirm the presence of spirochetes in the selected fields.  
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genetic manipulation of B. hermsii YOR resulted in plasmid loss, the plasmid compositions of 
Bh YOR::kan
r
gfp and Bh YORΔfhbA were assessed by pulsed-field gel electrophoresis (PFGE). 
This approach revealed the plasmid profiles of the parental and transformant strains to be 
indistinguishable (Figure 3). Additionally, growth curve analyses demonstrated that Bh 
YOR::kan
r
gfp and Bh YORΔfhbA grow normally in culture (Figure 4), suggesting that neither 
insertion of the kan
r
gfp cassette nor deletion of fhbA interfere with in vitro viability.  
 
Analyses of FhbA/factor H-binding protein expression 
 Expression and cell-surface presentation of FhbA were assessed by immunoblot analyses 
coupled to Proteinase K digestion. Following incubation either with Proteinase K or with PBS 
alone, cells of each B. hermsii YOR strain were solubilized, fractionated by SDS-PAGE, and 
probed with anti-FhbA antiserum. Bh YOR::kan
r
gfp was found to express FhbA after treatment 
with PBS, but not after digestion with Proteinase K, demonstrating that kan
r
gfp cassette insertion 
does not interfere with cell-surface expression of the adjacent fhbA gene (Figure 5A). Bh 
YORΔfhbA, however, failed to express FhbA under control or experimental conditions, 
suggesting elimination of FhbA expression in this strain (Figure 5A). Factor H affinity ligand 
binding immunoblot (FH ALBI) analysis was performed to further assess factor H-binding 
protein expression. Untreated B. hermsii cells were solubilized, immunoblotted, and incubated 
with purified human FH. Proteins capable of retaining FH were detected using anti-FH 
antiserum. Wild type B. hermsii YOR (Bh YOR-wt) and Bh YOR::kan
r
gfp bound FH to an ~20.5 
kDa protein presumed to be FhbA, while no Bh YORΔfhbA proteins capable of binding FH were 
identified (Figure 5B). For both assays, identical blots were screened with antiserum against the  
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Figure 3. Assessment of plasmid content by PFGE. The plasmid content of each B. 
hermsii YOR strain was assessed using pulsed-field gel electrophoresis (PFGE) and 
ethidium bromide staining. DNA size standards (in kb) are indicated to the left of the 
panel. 
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Figure 4. Growth curve analyses. Growth curves for each B. hermsii YOR strain were 
determined through microscopic cell counts (400X magnification) of equivalently 
inoculated cultures each day for seven days. The growth curves of Bh YOR::kanrgfp and 
Bh YORÄfhbA were compared to the growth curve of the parental wild type strain (Bh 
YOR-wt) in separate experiments, presented in Panel A and Panel B, respectively.  
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Figure 5. Analyses of FhbA expression by immunoblot and FH ALBI. FhbA 
expression was assessed (A) by immunoblot analysis of spirochetes that were pre-treated 
with or without Proteinase K, and (B) by FH ALBI analysis. The ALBI assay was 
performed by incubating immunoblots of lysates from untreated cells with purified 
human FH. After washing, FH bound by membrane-immobilized B. hermsii proteins was 
detected using anti-FH antiserum. In both assays, identical blots were screened with anti-
FlaB antiserum to confirm equal sample loading. For the Proteinase K assay, this control 
additionally demonstrated specific digestion of surface-exposed proteins. 
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periplasmic flagellar protein FlaB to demonstrate equal loading of samples and, for the 
Proteinase K assay, specific digestion of surface-exposed proteins. 
 
Analysis of the role of FhbA in whole-cell adsorption of FH 
 Although previous studies (78, 106) suggest that FhbA is the only factor H-binding 
protein produced by B. hermsii, the contribution of FhbA to the factor H-binding phenotype has 
not been directly assessed. To evaluate this under biologically relevant conditions, we incubated 
whole spirochetes with purified human FH. After washing, cell surface adsorption of FH was 
assessed. When screened by immunofluorescence assay (IFA), Bh YOR-wt and Bh 
YOR::kan
r
gfp cells demonstrated cell-surface FH adsorption, while FH was not detected in 
association with Bh YORΔfhbA cells (Figure 6A). Screening of FH-treated cells by immunoblot 
analysis also showed that Bh YOR-wt and Bh YOR::kan
r
gfp, but not Bh YORΔfhbA, adsorb FH 
from human serum (Figure 6B). 
 
Analysis of C3b inactivation  
Wild type B. hermsii cells that have been pre-incubated with FH are able to inactivate 
C3b in a factor I-mediated manner (106). To assess whether this ability is lost with abrogation of 
FH binding, strains of B. hermsii YOR were incubated with or without FH, washed, and then 
incubated with C3b in the presence of factor I. None of the strains displayed inherent C3b-
cleavage ability, and only intact C3b α’ and  chains (which migrate separately under reducing 
conditions) were detected in the reaction mixtures of non-FH-adsorbed cells (Figure 7). When 
pre-incubated with FH, however, the FhbA-expressing Bh YOR-wt and Bh YOR::kan
r
gfp strains 
degraded C3b. This was evidenced by the accumulation of α’43 and α’68 C3b cleavage products  
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Figure 6. Assessment of factor H binding through whole-cell adsorption assays. 
Intact cells of each B. hermsii YOR strain were incubated with purified human FH. To 
detect surface-adsorbed FH, the cells were analyzed by (A) immunofluorescence assay 
(DF=darkfield microscopy, FM=fluorescence microscopy), and (B) immunoblot analysis. 
Screening for both assays was performed using anti-human FH antiserum and appropriate 
secondary antibodies. During immunoblot analysis, an identical blot was screened with 
anti-FlaB antiserum to demonstrate equal loading of samples. 
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in the respective reaction mixtures (comparable to the cleavage products generated by the 
purified FH control). In contrast, Bh YORΔfhbA failed to cleave C3b regardless of FH pre-
incubation (Figure 7). 
 
FhbA expression and the binding of plasminogen by B. hermsii YOR 
 Binding of plasminogen/plasmin by Borrelia may play an important role in invasion and 
dissemination within the host (37, 117). In addition to binding FH, B. hermsii FhbA has been 
shown to bind other host-derived serum proteins including plasminogen (76). The effect of fhbA 
deletion on B. hermsii plasminogen-binding ability was assessed by ELISA. Although slightly 
decreased levels of bound plasminogen were detected for Bh YORΔfhbA as compared to Bh 
YOR-wt, all strains bound plasminogen at levels well above background (as established by 
controls) (Figure 8).  
 
Comparative analyses of serum sensitivity and C9 deposition 
To assess the role of FhbA in complement evasion in vitro, B. hermsii wild type and 
transformant strains were incubated with either normal, complement-active serum (designated 
NHS) or heat-inactivated human serum (hiNHS). Serum sensitive B. andersonii isolate MOD-1 
served as a control. At 2, 6, and 24 hours, the bacteria were examined for viability using 
BacLight LIVE/DEAD staining. Consistent with previous results (76), Bh YOR-wt remained 
resistant to killing in normal human serum, as did transformant strain Bh YOR::kan
r
gfp (Figure 
9A). In contrast, B. andersonii was largely killed within 2 hours, confirming the complement 
activity of the normal serum. Despite being unable to inactivate C3b through FH/FI-mediated  
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Figure 7. Analysis of C3b cleavage. Cells of each B. hermsii YOR strain were pre-
treated with or without FH, as indicated, prior to incubation with factor I and C3b. As a 
control, FH, factor I, and C3b were co-incubated in solution. Following removal of cells, 
the reaction mixtures were immunoblotted and screened with anti-C3 antiserum. 
Expected sizes of the C3b á’ and â chains, as well as the factor-I mediated C3b cleavage 
products á’43 and á’68, are indicated to the right of the panel.  
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Figure 8. Analysis of the effects of fhbA deletion on B. hermsii plasminogen binding. 
Cells of each B. hermsii YOR strain were immobilized into 96-well plates, incubated 
with plasminogen, and screened by ELISA to detect bound plasminogen. Controls 
consisted of Bh YOR-wt cells incubated with BSA alone (No plasminogen) and uncoated 
wells incubated with plasminogen (No cells). All samples were run in triplicate. Error 
bars represent standard deviation. 
42
cleavage (Figure 7), Bh YORΔfhbA did not display increased serum sensitivity and remained 
resistant to killing out to 24 hours (Figure 9A). 
Although both Bh YORΔfhbA and B. andersonii MOD-1 lack the ability to bind FH, the 
latter displayed a high degree of serum sensitivity while Bh YORΔfhbA remained serum 
resistant. To explore this discrepancy, an assay was performed to assess cell-surface deposition 
of complement protein C9, an integral component of the cytolytic membrane attack complex 
(MAC), following incubation in serum. Cells were incubated in 10% NHS or hiNHS, washed, 
and screened by ELISA using anti-C9 antiserum. Consistent with its high degree of serum 
sensitivity, B. andersonii MOD-1 underwent significant C9 deposition in complement-active 
serum, while minimal deposition was seen on the FH-binding, serum resistant strains Bh YOR-
wt and Bh YOR::kan
r
gfp (Figure 9B). Interestingly, Bh YORΔfhbA did not undergo increased C9 
deposition, suggesting a molecular basis for its ability to resist destruction in complement-active 
serum. 
 
Demonstration of the ability of B. hermsii YOR transformants to infect and persist in mice 
To determine if B.hermsii YOR transformant strains are infectious, mice (n=5) were 
needle inoculated and blood was collected at 0, 3, 4, 7, 10, 14, 18, and 42 days post-inoculation. 
Spirochetemia was measured by microscopic counts of organisms in 5 μl blood (diluted 1:20 in 
sodium citrate anticoagulant and PBS). All B. hermsii YOR strains were infectious and reached 
comparable levels in the bloodstream (Figure 10A). Only a single spirochetemic peak, on Day 4 
of infection, was observed for all infecting strains. However, Bh YOR-wt and Bh YOR::kan
r
gfp 
persisted through Day 14, and Bh YORΔfhbA through Day 18, in individual animals, as 
evidenced by re-cultivation of spirochetes from cultured blood samples (Table 3). All mice  
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Figure 9. Serum sensitivity analyses and assessment of C9 cell surface deposition.                
(A) Cells of B. andersonii MOD-1 (serum sensitive control) and each B. hermsii YOR 
strain were incubated with 50% normal human serum (NHS; closed circles) or heat-
inactivated human serum (hiNHS; open circles). Cell viability was assessed after 2, 6, 
and 24 hours of incubation using BacLight LIVE/DEAD staining and fluorescence 
microscopy. The mean percent survivals were calculated from counts of ten fields (400X 
magnification) per strain at each time point. (B) Deposition of complement component 
C9 on cells of B. andersonii MOD-1 (control) and B. hermsii strains was assessed by 
ELISA. Following incubation in 10% NHS or hiNHS, cells were immobilized into 
ELISA plates and screened with goat anti-C9 antiserum and an appropriate secondary 
antibody. Samples were run in triplicate, with error bars representing standard deviation.  
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developed significant and equivalent anti-B. hermsii IgG titers, indicating seroconversion (Figure 
10B). To verify the integrity of the infecting strains, an attempt was made to PCR amplify fhbA 
from each strain re-isolated from murine blood (obtained at peak spirochetemia, 4 days post-
inoculation) using primers TC2 and TC3 (Table 2). Amplicons were generated from each Bh 
YOR-wt and Bh YOR::kan
r
gfp isolate, but not from any isolate of Bh YORΔfhbA (Figure 11A). 
Additionally, screening of immunoblots of recombinant B. hermsii YOR FhbA (r-FhbA) with 
pooled infection sera from each experimental group demonstrated that an FhbA-specific IgG 
response was generated during infection with Bh YOR-wt  and Bh YOR::kan
r
gfp, but not during 
infection with Bh YORΔfhbA (Figure 11B).  
 
Demonstration of the in vivo stability of spirochetal GFP expression  
 To determine if the Bh YOR::kan
r
gfp and Bh YORΔfhbA transformant strains stably 
produce GFP during infection and upon re-isolation from mammals, fluorescence microscopy 
was performed on spirochetes recultivated from mouse blood in the absence of kanamycin (data 
not shown) and on diluted murine blood samples obtained during infection (Figure 12). All 
transformant spirochetes observed by microscopy produced GFP, demonstrating that GFP 
production by these strains is stable in vivo and upon release of antibiotic selection.  
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Figure 10. Analysis of infectivity and persistence in mice.  Mice (n=5) were infected 
with B. hermsii YOR strains by needle inoculation. (A) At days 3, 4, 7, 10, 14, and 18 
post-inoculation, peripheral blood samples were obtained and assessed for the presence of 
spirochetes by darkfield microscopy. Data are presented as number of spirochetes per ml 
of blood for each infecting strain at each time point. Calculations are detailed in the text. 
Error bars represent standard deviation. (B) To compare humoral immune responses 
elicited by each infecting strain (as indicated), murine anti-B. hermsii IgG titers were 
determined using serum harvested from mice 4 weeks post-inoculation and ELISA 
analysis. Whole cells of wild type B. hermsii YOR (Bh YOR-wt) served as the antigenic 
target. Experimental groups were compared based on geometric means (grey bars) of 
titers calculated for individual mice (triangles) at 1/3 maximum absorbance (OD405). 
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Table 3. Recultivation of spirochetes from blood of infected mice 
 
 
 
               
Strains    0 3 4 7 10 14 18 42 
 
Bh YOR-wt   0/5 5/5 5/5 5/5 5/5 1/5 0/5 0/5 
Bh YOR::kanrgfp  0/5 5/5 5/5 5/5 4/5 2/5 0/5 0/5 
Bh YORΔfhbA   0/5 5/5 5/5 5/5 5/5 3/5 2/5 0/5 
 
Data are shown as: (number of mice yielding positive blood cultures / total number of mice)                     
at each time point (in days) post-inoculation 
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Figure 11
Bh YOR-wt rBh YOR::kan gfp Bh YORÄfhbA
A B C D E A B C D E
0.5-
A B C D E
kb
A
Bh YORÄfhbAr
Bh YOR::kan gfp
Uninfected
Bh YOR-wt
-
25
20
-
kDa
r-FhbA
B
Figure 11. Serological and PCR-based analyses of infectious B. hermsii strains. (A) All B. 
hermsii YOR strains recultivated from the blood of individual mice (A-E, indicated above the 
panel) were analyzed by PCR using fhbA-specific primers (TC2/TC3; Table 2). Associated 
ethidium-bromide stained amplicons are shown. (B) The ability of each strain to elicit an FhbA-
reactive IgG response during murine infection was assessed by screening identical r-FhbA 
immunoblots with infection sera (pooled by infecting strain, as indicated below each panel) 
obtained from mice 4 weeks post-inoculation. 
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Figure 12
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Figure 12. Demonstration of in vivo GFP production. Darkfield and fluorescence 
microscopy (DF and FM) were used to analyze spirochetal GFP production in diluted 
blood samples obtained from infected mice four days post-inoculation.  
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Discussion 
   
 Genetic manipulation techniques have been used to study multiple aspects of the biology 
and virulence of the LD spirochete B. burgdorferi. Prior to this study, however, there has been 
only a single report of successful genetic manipulation of a TBRF spirochete (17). Battisti and 
colleagues inactivated the vtp gene, which encodes the variable tick protein (Vtp), by replacing 
vtp with an antibiotic resistance cassette through site-directed allelic exchange. This study was 
performed using B. hermsii DAH clone 2E7 (a GGI strain) and standard methods of electro-
transformation. While Vtp was found to be nonessential for infectivity in mammals, this earlier 
report served as the first demonstration that foreign DNA can be introduced in a site-specific 
manner into a TBRF spirochete.  
 In this work, we generated a clonal population of B. hermsii strain YOR that harbors a 
selectable marker (kan
r
) and constitutively expresses a fluorescent marker (gfp). To achieve this, 
a suicide vector, pFAEV3, was constructed and electroporated into B. hermsii YOR. A major 
obstacle in the genetic manipulation of B. burgdorferi is that infectious strains often have very 
low transformation efficiencies (1-1000 transformants μg-1 DNA (91, 136), as opposed to >107 
μg-1 DNA for E. coli) for reasons that remain unclear. The limitations imposed by this 
intractability can generally be overcome by use of very large amounts of transforming DNA (up 
to 50 μg per 109 cells) (166). Here, because the transformation efficiency of B. hermsii was 
unknown, plasmid DNA was utilized at a high concentration of 25 μg per reaction (~109 cells). 
Transformation of B. hermsii YOR resulted in the insertion of the kan
r
-gfp cassette into a non-
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coding sequence of  lp200 between the fhbA gene and a hypothetical ORF. lp200 was chosen to 
harbor the integration site due, in part, to the availability of sequence for this plasmid and its 
wide distribution and stability among B. hermsii isolates (78, 79). 
 In our initial attempts to perform genetic transformation of B. hermsii, we employed the 
spectinomycin-streptomycin resistance gene aadA, fused to a B. burgdorferi flgB promoter (59), 
for selection. Although the utility of this cassette in B. burgdorferi has been well established (50, 
59, 84), multiple (>20) individual attempts to generate B. hermsii YOR transformants using this 
resistance cassette were uniformly unsuccessful. Although B. burgdorferi B31 and B. hermsii 
DAH flgB promoters are very similar (94% sequence identity), the use of certain foreign 
promoters has been shown to decrease expression of antibiotic resistance genes in Borrelia (21). 
Therefore, we reconstructed our vector in order to incorporate a kanamycin resistance gene 
(kan
r
) (used with success in B. hermsii previously (17)) linked to a native B. hermsii DAH flgB 
promoter. When the remodeled pFAEV3 vector was subsequently used in transformation 
experiments, 33% of electroporation reactions yielded positive transformants. It is not clear if the 
promoter element or the kan
r
 resistance gene (or both) enabled successful transformation, but no 
conditions beyond those were altered between experimental attempts. 
 Having successfully established a protocol for transformation of  B. hermsii YOR, we 
reasoned that similar methods could be extended to study specific B. hermsii virulence 
mechanisms. Of particular interest was the immune evasive mechanism of FH binding. Many 
pathogens produce proteins able to bind FH at the cell surface, thereby exploiting its function as 
a negative regulator of the complement cascade (61, 74, 112, 113, 140). In several pathogenic 
spirochetes, including the Borrelia, FH-binding ability appears to correlate with complement 
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resistance and, potentially, infective potential (23, 76, 86, 101, 108, 131). However, direct 
evidence of the role of FH-binding in the Borrelial disease process is lacking.  
 B. hermsii is an ideal model system in which to study this process. For B. burgdorferi, 
which produces five factor H-binding proteins (CspA; CspZ; and OspE family proteins BBN38, 
BBL39, and BBP38), complete elimination of the FH-binding phenotype would require 
inactivation of multiple genes on various plasmids. While cspA (bbA68) and cspZ (bbh06) have 
been inactivated individually (23, 36), the inactivation of five Borrelial genes simultaneously is 
beyond the scope of current techniques. In contrast, B. hermsii produces only one factor H-
binding protein, FhbA. fhbA is a single copy gene with no known paralogs, is transcribed as a 
monocistronic message, and is separated from putative upstream and downstream ORFs by >100 
bases (78). Collectively, these factors recommended fhbA as a highly useful and feasible target 
for mutagenesis.  
Genetic manipulation methods were repeated to generate a B. hermsii YOR fhbA deletion 
mutant (Bh YORΔfhbA) using the pFAEV3ΔfhbA allelic exchange vector and electroporation. 
Transformation with this vector resulted in deletion of the fhbA coding region from lp200 and 
integration of the kan
r
-gfp cassette through a double-crossover event.  
 Following transformation and recovery in liquid culture, clonal populations of Bh 
YOR::kan
r
gfp and Bh YORΔfhbA were derived through limiting dilution. For unknown reasons, 
efforts to generate clonal populations using the standard sub-surfacing plating methods 
developed for B. burgdorferi (136) were not successful. PCR analyses and fluorescence 
microscopy were performed to verify successful transformation and GFP expression.  
An additional challenge in the genetic manipulation of B. burgdorferi is loss of 
endogenous plasmids that encode proteins required for survival in either tick or mammalian 
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hosts (91, 124, 132). In B. burgdorferi, plasmid content is typically assessed by PCR using 
plasmid-specific primer sets  (87, 105, 124). However, while the sequence of the B. hermsii 
DAH chromosome is available, sequences for the plasmids are not. Hence, plasmid-specific PCR 
could not be applied for this purpose here. Instead, plasmid profiles of the B. hermsii YOR wild 
type and transformant strains were assessed by pulsed field gel electrophoresis (PFGE). We did 
not observe any differences in plasmid profiles between strains, although it is possible that some 
B. hermsii plasmids were not discerned by this approach due to size similarities and co-migration 
patterns. Additionally, growth curve analyses demonstrated comparable growth rates between 
transformant and parental strains. This verified that neither insertion and expression of kan
r
gfp 
nor deletion of fhbA interfere with in vitro viability, and provided additional evidence that 
plasmids necessary for growth were not lost during transformation.  
To analyze expression and cell-surface presentation of FhbA, cells of each strain were 
incubated with or without Proteinase K, then fractionated by SDS-PAGE. Immunoblot analyses 
using antiserum directed against FhbA demonstrated that while Bh YOR::kan
r
gfp expressed 
FhbA at the cell surface, FhbA was not expressed by Bh YORΔfhbA. To further assess 
FhbA/factor H-binding protein expression, untreated cell lysates were fractionated by SDS-
PAGE and analyzed by FH ALBI.  This assay detects membrane-immobilized spirochetal 
proteins capable of binding FH. As anticipated, Bh YOR-wt and Bh YOR::kan
r
gfp bound FH to a 
single ~20 kDa protein consistent in size with FhbA, while no proteins produced by the fhbA 
deletion mutant displayed FH-binding ability.  
 One limitation of  the FH ALBI assay as performed here is that reducing and denaturing 
conditions may alter sample properties and conformation prior to analysis. Therefore, it is 
possible that certain proteins capable of binding FH under nondenaturing, physiologic conditions 
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may not be detected by this method. The Bh YORΔfhbA mutant strain provides a unique 
opportunity to examine physiologic B. hermsii FH binding through a whole cell adsorption 
assay. Here, cells of each strain were incubated in purified human FH, washed, then screened for 
cell-surface FH adsorption using anti-FH antibodies. Both IFA and immunoblot screening 
methods demonstrated that FhbA-positive, but not FhbA-negative, cells adsorbed FH to the cell 
surface. This result provides the first direct evidence that FhbA is B. hermsii’s sole factor H 
binding protein and that its deletion results in complete loss of the FH-binding phenotype. 
Consistent with this, Bh YORΔfhbA was unable to cleave and inactivate complement protein 
C3b in the presence of factor I and following incubation with factor H. This almost certainly is a 
functional consequence of its inability to bind FH. Data here and in previous studies demonstrate 
that B. hermsii YOR  lacks inherent C3b cleavage abilities (e.g., through production of 
proteases), but rather binds FH in a functionally active manner that permits cofactor activity in 
the factor-I mediated cleavage of C3b (106).  
 In addition to FH, FhbA has been shown to interact with multiple host ligands including 
plasminogen (76). To assess the contribution of FhbA to whole-cell plasminogen binding, plate-
immobilized cells of each strain were incubated with plasminogen, washed, and screened using 
anti-plasminogen antibodies. This binding assay revealed that levels of retained plasminogen 
appeared marginally decreased for Bh YORΔfhbA as compared to Bh YOR-wt; however, all 
strains demonstrated clear plasminogen-binding ability as compared to controls. This suggests 
that although FhbA may contribute to cumulative plasminogen acquisition by B. hermsii YOR, 
alternate mechanisms likely compensate for the loss of FhbA expression. Therefore, an attempt 
to identify additional B. hermsii plasminogen-binding proteins may be warranted. 
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 Previous studies have demonstrated that B. hermsii high passage strain REN, which lacks 
fhbA, exhibits increased sensitivity to killing in serum and an inability to persist in, but not to 
infect, mice (76). To examine whether deletion of fhbA in strain YOR similarly impacts serum 
resistance, all B. hermsii YOR strains, as well as B. andersonii MOD-1 (a non-FH-binding, 
serum sensitive control strain) were incubated in normal, complement-active human serum 
(NHS) or in serum rendered complement-inactive through heat treatment (hiNHS). Intriguingly, 
while B. andersonii was rapidly killed in complement-active NHS, all B. hermsii YOR strains 
exhibited a high degree of serum resistance in NHS out to 24 hours. Analyses of cell-surface C9 
deposition on similarly treated cells provided insight into the molecular basis of these 
observations, as B. andersonii MOD-1 was found to bear high levels of membrane-associated 
C9, a terminal MAC component. All B. hermsii strains, however, including Bh YORΔfhbA, were 
spared such deposition. Consistent with these results, infection analyses in C3H/HeJ mice 
demonstrated Bh YORΔfhbA to be fully infectious, generating spirochetemias and eliciting anti-
B. hermsii IgG responses equivalent to Bh YOR-wt and Bh YOR::kan
r
gfp. Unlike FhbA-negative 
B. hermsii strain REN, which reached high levels during initial infection then was prematurely 
cleared, Bh YORΔfhbA was cultured from the blood of individual mice at Day 18, a time point 
beyond when Bh YOR-wt and Bh YOR::kan
r
gfp had been eliminated from their respective hosts. 
Although only moderately reliable in the clinical setting (5, 62, 116, 137, 154), direct 
microscopic examinations of peripheral blood samples are widely used to monitor RF infections 
under laboratory conditions (4, 65, 95, 152) where disease kinetics can be anticipated and 
assessed over a broad temporal range. Nonetheless, sample size inherently constrains the 
sensitivity of this method (46), and the detection limit here was approximately 4 x 103 
spirochetes ml
-1
 murine blood. Direct blood culturing, when successful, offers increased 
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detection sensitivity (here, a theoretical limit of 167 spirochetes ml
-1
 blood), but not quantitative 
assessment of spirochete burden. Coupling of these assays allowed us to assess and compare 
various aspects of infections produced by each B. hermsii strain. Although highly sensitive PCR-
based molecular diagnostic techniques for RF have been developed (typically targeting the 16S 
rRNA or glpQ genes, or the rrs–rrlA intergenic spacer region (5, 116, 137)), they are cost- and 
labor-intensive and thus are not typically employed for routine spirochetemic monitoring.  
Because limiting dilution is not a standard method of establishing clonal populations in 
the Borrelia, additional assays were performed to ensure that the observed infections were in fact 
caused by transformant populations and not by the rare wild type variant that was able to 
proliferate in the in vivo environment. PCR analysis demonstrated that fhbA could be amplified 
from all strains recultivated from Bh YOR-wt- and Bh YOR::kan
r
gfp- infected mice, but not 
from strains recultivated from mice infected with Bh YORΔfhbA. Consistent with this, sera from 
mice infected with Bh YOR-wt and Bh YOR::kan
r
gfp were reactive against recombinant FhbA 
protein, but sera from YORΔfhbA-infected mice and from uninfected mice were nonreactive. 
Stable expression of GFP was observed for all transformant strains both in murine blood samples 
during infection and in culture (without kanamycin selection) following recultivation from blood. 
This provides important confirmation that the gfp insertion is stably maintained in the B. hermsii 
genome. 
 In summary, Bh YORΔfhbA does not produce FhbA or bind factor H. Because it lacks 
FH-binding abilities, this strain is unable to cleave and inactivate C3b in solution. However, Bh 
YORΔfhbA is not susceptible to C9 deposition, as is reflected in its high degree of serum 
resistance, and is infectious and able to persist in a murine host. This suggests that B. hermsii can 
evade complement activation via one or multiple non-FH-mediated mechanisms. Such potential 
58
mechanisms may involve binding or production of additional factors capable of negatively 
regulating the complement cascade. Although pathogen exploitation of FH in particular has been 
heavily scrutinized, studies have identified a plethora of additional evasive mechanisms 
involving host complement regulatory proteins (89). These proteins include both early 
(complement receptor type 1 (CR1), membrane cofactor protein (MCP), decay-accelerating 
factor (DAF)) and late (vitronectin, CD-59) regulators of the alternative complement pathway 
(Figure 13). Membrane-associated regulators, such as CR1, MCP, DAF, and CD-59, are broadly 
distributed across the surfaces of most mammalian host cells, where they act to control local 
complement activation along with performing a variety of additional functions. Important fluid-
phase regulators of alternative complement activation include both FH and vitronectin, soluble 
proteins present in host plasma and some body fluids (175). Actions of alternative pathway 
regulatory proteins fall into three general groups: inactivation of C3b through factor I-mediated 
cleavage, destabilization of the C3bBb C3 convertase, and interference with terminal component 
assembly/membrane insertion (110) (Figure 13). Based on the results of the C3b assay presented 
here (Figure 7), B. hermsii YOR does not appear to produce endogenous factors that fall into the 
first category (i.e., participate in factor I-mediated C3b cleavage). Of particular interest, 
however, are the potential roles in B. hermsii complement evasion of vitronectin or a CD-59-like 
protein, both of which interact with terminal complement components to prevent MAC 
formation (110). The former would represent a novel mechanism in Borrelia (although it is 
employed by other pathogens, such as Moraxella catarrhalis (6, 153)), while the latter has been 
documented previously in B. burgdorferi (121).  
In conclusion, these results collectively suggest that TBRF spirochete B. hermsii YOR 
employs an unidentified, FH-independent mechanism of complement evasion that is sufficient  
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Figure 13. Negative regulators of the alternative complement pathway. Fluid-phase 
regulator factor H and cell-surface regulators CR1, DAF, and MCP inhibit alternative 
complement activation through both cofactor activity in the factor I-mediated cleavage of 
C3b and decay acceleration/destabilization of the C3 convertase (C3bBb). Vitronectin, a 
soluble regulator, prevents MAC formation by interacting with and blocking membrane 
insertion of the terminal C3b5-8 assemblage. Membrane protein CD-59 inhibits MAC 
formation by interacting with membrane-associated C3b5-8/-9 and preventing C9 
incorporation and polymerization. These mechanisms are employed by the host to 
prevent inappropriate and injurious complement activation, but can be exploited by 
pathogens during the infectious process.  
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for persistence within the host. Whether this mechanism is direct and non-redundant, or 
multifactorial and complex, continued analyses of Bh YORΔfhbA and generation of  novel RF 
spirochete mutants may prove critical to its elucidation.    
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